Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Arcturus Therapeutics Holdings's Capital Expenditure for the three months ended in Dec. 2023 was $-0.88 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-18.27 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Arcturus Therapeutics Holdings Capex-to-Operating-Income Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Capex-to-Operating-Income Chart

Arcturus Therapeutics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

0.63

Arcturus Therapeutics Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial															0.03	0.05	-	-	-

Competitive Comparison of Arcturus Therapeutics Holdings's Capex-to-Operating-Income

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcturus Therapeutics Holdings's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Capex-to-Operating-Income falls into.

Arcturus Therapeutics Holdings Capex-to-Operating-Income Calculation

Arcturus Therapeutics Holdings's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-2.901)	/	-78.205
	=	N/A

Arcturus Therapeutics Holdings's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.875)	/	-18.272
	=	N/A

Arcturus Therapeutics Holdings (NAS:ARCT) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Arcturus Therapeutics Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121

Website

https://www.arcturusrx.com

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Executives

Pad Chivukula	officer: Chief Scientific Officer & COO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld	officer: See Remarks	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne	director, 10 percent owner, officer: President and CEO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc.	director, 10 percent owner	60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata	officer: Chief Legal Officer	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine	officer: Chief Financial Officer	82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes	officer: Chief Development Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow	director	2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes	director	C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949